BioPharma Clinical Trials

Reacta Healthcare Completes First Pharmaceutical-Grade Production of Egg and Milk Challenge Meals

1st production of pharmaceutical grade egg and milk challenge meals Product portfolio of challenge meals now includes peanut, milk and egg Innovat...

 June 13, 2025 | News

Specialised Therapeutics Expands Incyte Partnership to Launch Axatilimab and Retifanlimab in Asia-Pacific

Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agree...

 June 13, 2025 | News

Sweden’s Salipro Biotech Partners with South Korea’s Daewoong Pharmaceutical to Target Challenging Drug Discovery

- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance...

 June 12, 2025 | News

Abbisko Therapeutics’ Pimicotinib NDA Accepted by China NMPA for Tenosynovial Giant Cell Tumor

Abbisko Therapeutics Co., Ltd.  announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) f...

 June 11, 2025 | News

Nuevocor Receives FDA IND Clearance to Advance NVC-001 Gene Therapy for LMNA-Related Dilated Cardiomyopathy

LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United...

 June 11, 2025 | News

ImmVira Doses First NMIBC Patient in Multi-Regional Phase II Trial of Novel Oncolytic Immunotherapy MVR-T3011

 ImmVira, a global leading clinical-stage biotechnology company focused on the development of next-generation novel oncolytic immunotherapy for treatm...

 June 11, 2025 | News

VivaVision Receives Positive FDA Feedback on VVN461LD Phase 2 Trial for Ocular Inflammation

VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced today t...

 June 10, 2025 | News

Eluminex Reports Positive Phase 1 Results for EB-105 in Diabetic Macular Edema Patients

EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6R Improvements in Visual Acuity and Retinal Edema Observed at All Dose Levels No Safety Issues Observed...

 June 10, 2025 | News

GenEditBio Doses First Patient in World's First In Vivo CRISPR Trial for TGFBI Corneal Dystrophy

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery o...

 June 09, 2025 | News

ASCO 2025 Showcases New Oncology Paradigms, From Breast Cancer Breakthroughs to AI-Led Precision Medicine

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting wasn’t just another scientific gathering and it was a seismic event that redrew ...

 June 06, 2025 | Report

QureBio Secures Nearly CNY 100 Million in Series C1 Funding Led by Efung Capital

Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 mil...

 June 06, 2025 | News

Innovent Secures Second NMPA Breakthrough Therapy Designation for IBI363 in Advanced Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

 June 05, 2025 | News

Akeso’s Cadonilimab Secures NMPA Approval for First-Line Treatment of Cervical Cancer

Akeso, Inc. is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecif...

 June 05, 2025 | News

XellSmart Advances Global Leadership in iPSC-Derived Cell Therapies for CNS Disorders

XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell the...

 June 03, 2025 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close